Results for this period
Full year1 June 2025 to 31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Existing-store sales exceeded the previous year due to the continuation of EDLP initiatives. The number of dispensing pharmacy stores increased, cooperation with nearby medical institutions was strengthened, and the calculation of various reimbursement add-ons was expanded, resulting in steady trends in the number and average value of prescriptions filled. Securing gross profit through the effect of higher revenue and appropriate control of selling, general and administrative expenses also contributed to the increase in profit.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2025 to 31 May 2026 |
| Net Sales | ¥497,128 million (YoY +8.8%) |
| Operating profit | ¥23,970 million (YoY +5.9%) |
| Ordinary income | ¥25,232 million (YoY +7.8%) |
| Profit attributable to owners of the parent | ¥16,990 million (YoY +8.3%) |
| Net income per share | ¥263.00 |
| Operating Margin | Current fiscal year 4.8 % / Previous period 4.9 % |
| Equity ratio | End of the current fiscal period 60.4 / End of previous period 60.3 |
| Total assets | ¥255,350 million |
| Net assets | ¥154,321 million |
| Cash flows from operating activities | ¥25,435 million |
| Cash flows from investing activities | ¥-20,405 million |
| Cash flows from financing activities | ¥-5,678 million |
| Cash and cash equivalents at end of period | ¥36,699 million |
| Full-year earnings forecast | Net Sales ¥541,000 million (YoY +8.8%) / Operating profit ¥25,300 million (YoY +5.5%) / Ordinary income ¥26,500 million (YoY +5.0%) / Net income ¥17,000 million (YoY +0.1%) / Net income per share ¥263.15 |
| Annual Dividend Forecast | ¥93 → ¥96（+3.2%） |
| Payout ratio | Actual results for the fiscal year ended May 2026 35.4 % / Forecast for the fiscal year ending May 2027 36.5 % |
| Regional sales | ¥299,853 million, ¥68,063 million, ¥52,135 million, ¥46,782 million, ¥30,293 million |
| Depreciation and amortization | ¥6,442 million |
| Impairment loss | ¥1,538 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Subsidy Income ¥109 million / Extraordinary loss Loss on sale of fixed assets ¥0 million, Impairment Losses ¥1,538 million, Loss on Disposal of Fixed Assets ¥0 million, Loss on reduction of fixed assets ¥109 million, Other ¥10 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 3 / Company name 株式会社サンエフ, 株式会社八百半ホールディングス, 株式会社八百半フードセンター / Excluded Number of companies 1 / Company name 株式会社サンエフ |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Securities analysts and institutional investors |
| Issued Shares at Period-End | 66,819,342 |
| Treasury Shares at Period-End | 2,217,078 |
| Factors Behind Changes in Business Performance | Existing-store sales exceeded the previous year due to the continuation of EDLP initiatives. The number of dispensing pharmacy stores increased, cooperation with nearby medical institutions was strengthened, and the calculation of various reimbursement add-ons was expanded, resulting in steady trends in the number and average value of prescriptions filled. Securing gross profit through the effect of higher revenue and appropriate control of selling, general and administrative expenses also contributed to the increase in profit. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Existing-store sales exceeded the previous year due to the continuation of EDLP initiatives. The number of dispensing pharmacy stores increased, cooperation with medical institutions was strengthened, and the calculation of various reimbursement add-ons was expanded, resulting in steady trends in the number and average value of prescriptions filled. Securing gross profit through higher revenue and appropriate control of selling, general and administrative expenses also contributed to the increase in profit.